title: Interleukin-1 receptor antagonist improves survival and preserves organ adenosine-5'-triphosphate after hemorrhagic shock.
abstract: BACKGROUND
  This study was designed to determine the role of interleukin-1 (IL-1) in hemorrhagic shock death.
  
  
  METHODS
  Pentobarbital anesthetized C3H/HeN mice (n = 59) were prepared with a femoral arterial catheter and were randomized to treatment with an IL-1 receptor antagonist (IL-1ra, 10 mg/kg, n = 29) or an equal volume of phosphate-buffered saline solution (vehicle, n = 30) by subcutaneous bolus injection at 15 minutes before hemorrhage and again at 120 minutes. Continuous posthemorrhage delivery of IL-1ra or vehicle was performed in each group (1.5 mg IL-1ra in 30 microliters/day) through a subcutaneous osmotic pump. Rapid hemorrhage of 4 ml/100 gm weight was followed by normal saline resuscitation of 12 ml/100 gm 60 minutes later.
  
  
  RESULTS
  Survival analysis by Wilcoxon rank sum analysis revealed a significantly improved 5-day survival in IL-1ra-treated mice (n = 15, 20%) as compared with vehicle-treated mice (n = 14, 6%, p < 0.001). To determine a possible mechanism of this survival advantage, the remaining mice in each treatment group were killed at 30 minutes to obtain blood and tissue samples from the heart, liver, and kidney for measurement of adenosine-5'-triphosphate (ATP). No difference in hematocrit, circulating neutrophils, or levels of glucose, lactate, or tumor necrosis factor was identified between groups to explain the improved outcome. IL-1ra prevented hemorrhage-induced ATP depletion observed in vital organs of vehicle-treated mice.
  
  
  CONCLUSIONS
  The data implicate IL-1 in shock-induced ATP depletion and suggest IL-1ra may improve hemorrhagic shock survival by preventing ATP depletion in vital organs.
authors.affiliation: Department of Surgery, Medical College of Virginia/Virginia Commonwealth University, Richmond 23298-0475.
authors.forename: J V
authors.initials: JV
authors.lastname: Pellicane
authors.forename: E J
authors.initials: EJ
authors.lastname: DeMaria
authors.forename: A
authors.initials: A
authors.lastname: Abd-Elfattah
authors.forename: H D
authors.initials: HD
authors.lastname: Reines
authors.forename: J L
authors.initials: JL
authors.lastname: Vannice
authors.forename: K W
authors.initials: KW
authors.lastname: Carson
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism*; D000818:Animals; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000502:physiology*; D007773:Lactates / Q000097:blood; D019344:Lactic Acid; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D012771:Shock, Hemorrhagic / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality; D012795:Sialoglycoproteins / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: C507764:Il1rn protein, mouse; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D007773:Lactates; D012795:Sialoglycoproteins; D019344:Lactic Acid; D000255:Adenosine Triphosphate